ByRaktim Chattopadhyay, Founder & CEO, Esperer Nutrition
ByPranav Bajaj, Co-founder, Medulance
An allocation of budget for establishing mini-Anganwadi centers in deprived areas is another factor that will foster inclusive growth and welfare in the country. Meanwhile, the existing healthcare gap can be filled by introducing tax benefits and relaxations for private players and public-private partnerships.
At Medulance, we firmly believe that prevention is better than cure and a shift from reactionary and interventional healthcare to proactive healthcare is the need of the hour. It will also reduce the financial expenditure in the longer run. Finally, the pre-existing schemes such as Ayushman Bharat and NDHM must be strengthened in terms of their effectiveness and implementation for apparent results.
ByPrabhdeep Singh, Founder and CEO, StanPlus
We would appreciate it if the finance ministry recognises the industry's crucial need for ambulances and decreases the GST on new ambulance purchases from 28% to a 5% or a 12% slab. If fulfilled, this big step will encourage the acquisition of more ambulances and minimise the time it takes for patients to reach hospitals during medical emergencies.
ByDr JoginDesai,Founder and CEO of Eyestem
The government of India should invest in creating a plug and play product development hubs for newer treatments like cell and gene therapy on the lines of the UK (https://ct.catapult.org.uk/) and Canada (https://www.ccrm.ca/)
GOI should invest in providing national-level access to the science community for journal subscriptions which are prohibitively expensive.
ESOPs should be taxed only at the time of sale. Taxation at an earlier stage (at vesting) prevents startups from fully vesting these with employees which is essential to provide reassurance of ownership of the options.
ByAnish Bafna, CEO & MD, Healthium Medtech
The Finance Budget of FY 2021-22 had made a landmark allocation of 137% increase over FY21 in the healthcare sector, by allocating a total of INR 2,23,846 crore for healthcare. As the country faces the imminent third wave of the pandemic, the expectations are higher for a significant increase in the budget allocation into the healthcare sector to promote the preventive, curative, well-being and essential services’ sectors that have already started off on a high note to not only cater to the country but also the world.
ByHimesh Joshi, CEO & Co-Founder, Ayu Health Hospitals
As the country is gearing up for the third wave of the pandemic, the expectations are for greater budget allocation this year into the healthcare sector primarily for genetic research, aiding technology for early diagnosis in order to boost the capacity of our healthcare system to detect and cure new and emerging diseases in the aftermath of the Covid-19 pandemic. While the schemes like Ayushman Bharath were a step in the right direction, there is scope for amendments in the pricing structure where hospitals can provide high-quality healthcare services without incurring losses and also ease in the issues of delayed payouts to hospitals which are stretching into months for some schemes.
By Nikkhil K Masurkar, Executive Director, ENTOD Pharmaceuticals
"The pharmaceutical and medical devices industry has gained significant momentum owing to the government’s AatmaNirbhar Bharat initiative. The Union Budget 2022 is expected to build on the Production Linked Incentive (PLI) schemes and encourage continued investments in capacity expansion of sensitive APIs, drug intermediates, complex excipients, biopharmaceuticals and medical devices. While the draft R&D policy focuses on creating an ecosystem for research and innovation, certain tax incentives for the investment in ‘R&D focused funds’, set up for R&D based activities, could be introduced. India should participate in the innovation area at a global level. Along with a scheme similar to the PLI, the government needs to consider tax incentives to attract innovation. Interaction with industry and global players can help India's pharmaceutical sector to move from a generic manufacturer to an innovator developer and manufacturer for the world. Apart from that, Technology/digital transformation is another key area of focus. In fact, it would be the building block for the much-expected universal healthcare in India. Presently, GST on drugs is taxed under four categories - nil, 5%, 12% and 18%. While a few life-saving drugs are taxed at nil rates, some are taxed at 5 per cent and the majority fall under the 12 per cent GST slab. Extensions of a tax deduction on product development and R&D are some of the other demands of the pharmaceutical sector. The industry also seeks a 150% deduction in tax on in-house R&D.”
By Ashok Patel, CEO and Founder, Max Ventilator
"Apart from the need to raise the share of healthcare as a proportion of GDP to at least 2.5 percent in the upcoming budget, the government must also further build on its earlier policy incentives such as PLI schemes and dedicated medtech parks by increasing allocations. In fact, the government should ensure that the smaller medical device players also get included and can benefit from the special schemes and offers that it has extended with a view to catalyze domestic manufacturing and to achieve the larger goal of self-reliance. Given the repeated occurrences of infectious diseases of epidemic scale in recent years, the government should also invest sufficiently into genetic and genomic research, epidemiology and vaccine research besides increasing allocation for broader healthcare R&D. Of course, the diagnostics and preventive health device segment must be given as much policy and financial support as possible. Further, the budget could also incentivize the consumables as well as medical device accessory segments which hold huge promise for the domestic sector. At the same time, adequate allocation must be made for training of personnel required for the deployment and usage of critical care equipment such as ventilators and other similar lifesaving devices."
By Vikram Thaploo, CEO, Apollo Telehealth
"India is combating a massive global pandemic with its resources available in the health sector. The health sector is expecting more specific allotments in this year’s budget to mitigate Covid-19 and help in the growth of the telemedicine sector. The telemedicine segment is growing at a rapid pace and in the future, we are expecting more technological innovations to take place in the industry therefore, the budget should be well allocated to the healthcare sector to initiate new innovations to be prepared for the fight with pandemics like Covid-19 in the future. It is important especially in a country like India where digital health can truly provide care to areas with short supply of doctors. Increased allocation of budget for promotion of telemedicine, home-based healthcare and national digital health mission implementation will help in building a strong healthcare ecosystem in the country. Telemedicine has potential to improve access to healthcare in remote and rural areas. Home-based healthcare will reduce burden on limited healthcare facilities. Digital Health along with various innovations should be encouraged for India’s future growth in population health. The government should also support private players and startups in this segment to increase the current coverage of the locations including tier-2 and tier-3 cities to provide the advanced healthcare facilities in these areas."
By Akshay Daftary, Director, SIRO Clinpharm
"With the upcoming announcement of the Union Budget 2022 by Finance Minister Nirmala Sitharaman on February 1, the healthcare sector hopes for a boost in funding considering the importance of the sector in the light of the ongoing pandemic. Both individuals and governments place health high on their priority list and its importance has been amplified given the external environment and circumstances. While various flaws in the existing healthcare system in India were exposed during the pandemic in India, however, the government has reacted swiftly, by proposing reforms and policies that have played a role in addressing the problems.
While the Covid-19 is currently a focus and would remain at the forefront for the next few months, prevention and wellness should receive a greater share of funding to ensure drug development projects for life-saving therapies remain a strong priority. Our government has also taken a lot of efforts and measures to fight the Covid-19 pandemic and uplift our healthcare infrastructure. Apart from interim Covid-19 stimulus packages action pandemic prompted our government to increase allocation to the healthcare sector to 1.8 per cent of GDP in 2021 which was a 137 per cent increase over the previous year, this focus on healthcare should continue and I think our government should further increase healthcare spending to 2.5 per cent to 3 per cent of GDP this year and should not wait till 2025 to achieve the earlier target of increasing health care spending to 2.5 per cent of GDP.
European countries spending on healthcare is around 9 per cent of GDP. Long term aim of our country should be to reach that level within the next 7 to 10 years. Healthcare should be treated as a basic need of each citizen and should be made available to all at an affordable cost.
I would also like the government to give a further boost to the pharmaceutical and Clinical Research industry. I will be happy if the government does the following apart from increasing spending on healthcare:Nil or No GST or CRO offering clinical trials and allied services to pharmaceutical companies; Weighted deduction on Research and Development under Section 35(2AB) to increase to 200% to incentivise pharmaceutical companies to undertake more research and development work so that spending for new drug discovery and innovation can increase. Also, the scope of 35(2AB) to include FMCG and other companies in the research and development of products of medicinal use as well as a food supplement and nutrition and cosmetics.
Our country has a strong ambition to be a 5 trillion economy by 2025 and this will be difficult to achieve if we don’t take bold steps and support businesses in the healthcare sector to overcome the adverse effects of the Covid-19 pandemic and continue to play their role in facilitating drug development programs and ensure India’s pivotal role in the global healthcare scenario."